Biohaven (NYSE:BHVN) Shares Gap Up After Analyst Upgrade

Biohaven Ltd. (NYSE:BHVN) gapped up prior to trading on Monday after Bank of America raised their price target on the stock from $52.00 to $62.00. The stock had previously closed at $40.39, but opened at $46.50. Bank of America currently has a buy rating on the stock. Biohaven shares last traded at $48.90, with a volume of 1,921,258 shares changing hands.

Other equities research analysts also recently issued research reports about the company. Royal Bank of Canada increased their price objective on Biohaven from $59.00 to $68.00 and gave the company an “outperform” rating in a research report on Tuesday. Jefferies Financial Group started coverage on Biohaven in a report on Monday, September 16th. They set a “buy” rating and a $57.00 target price for the company. Leerink Partners lifted their price target on Biohaven from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday. Robert W. Baird upped their price objective on shares of Biohaven from $58.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Sanford C. Bernstein raised their target price on shares of Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a report on Tuesday. Thirteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $60.92.

Insiders Place Their Bets

In related news, Director John W. Childs purchased 28,400 shares of the stock in a transaction dated Thursday, July 18th. The shares were acquired at an average cost of $35.67 per share, for a total transaction of $1,013,028.00. Following the acquisition, the director now directly owns 2,339,741 shares in the company, valued at approximately $83,458,561.47. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 16.00% of the company’s stock.

Institutional Investors Weigh In On Biohaven

Large investors have recently made changes to their positions in the company. Redwood Wealth Management Group LLC bought a new position in Biohaven during the second quarter valued at approximately $61,000. Elkhorn Partners Limited Partnership bought a new position in shares of Biohaven during the 2nd quarter valued at $125,000. Quarry LP boosted its holdings in Biohaven by 614.3% in the second quarter. Quarry LP now owns 5,000 shares of the company’s stock worth $174,000 after purchasing an additional 4,300 shares in the last quarter. Prevail Innovative Wealth Advisors LLC acquired a new position in Biohaven during the fourth quarter worth $230,000. Finally, Capstone Investment Advisors LLC acquired a new position in Biohaven during the fourth quarter worth $235,000. Institutional investors own 88.78% of the company’s stock.

Biohaven Price Performance

The company has a fifty day simple moving average of $38.65 and a two-hundred day simple moving average of $40.65. The company has a market capitalization of $3.98 billion, a P/E ratio of -6.60 and a beta of 1.30.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($3.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($1.92). Equities analysts anticipate that Biohaven Ltd. will post -8.92 earnings per share for the current year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.